American Regent is conducting a voluntary nationwide recall of three lots of Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL) multi-dose vials after reports of leaking and cracked vials and the discovery of particulate contamination. The recall was announced September 3, 2026.
Exactly what is affected
The product carries NDC 0517-3030-01. Three lots are involved:
Lot 25128L1C0 (expiry August 2026), distributed September 4, 2025 to December 18, 2025. Lot 25280L1C0 (expiry October 2026), distributed December 16, 2025 to April 17, 2026. Lot 26108L1C0 (expiry July 2027), distributed June 15, 2026 to July 31, 2026.
This is a hospital and pharmacy bulk product, not a consumer epinephrine auto-injector. A 30 mL multi-dose vial is the format used in crash carts and intensive care units, where epinephrine is drawn up for cardiac arrest or diluted into continuous infusions for shock. Patients who carry an auto-injector for anaphylaxis are not affected by this recall.
What went wrong
The recall began with customer complaints about compromised vials — leaking and cracking. In regulatory terms that means a lack of assurance of sterility: the container closure system is what keeps an injectable product sterile through its shelf life, and once the glass is breached, that guarantee is gone regardless of how the drug was manufactured.
The company’s investigation then found particulate matter in the product, identified as nylon, cellulosic, acrylic, polyethylene and glass. That mix is telling — polymer and cellulosic fragments point toward processing or packaging materials, while glass is consistent with the cracking itself.
Why particles in an injectable are dangerous
Injectable medicines are held to strict particulate limits for a physical reason: anything that will not dissolve in blood has to go somewhere. Particles introduced intravenously travel until they reach a vessel too narrow to pass, and lodge.
The FDA notice lists the consequences: blockage of blood vessels, pulmonary embolism, organ damage, vein irritation and inflammatory reactions. Repeated or high-volume exposure carries additional risk of granuloma formation as tissue reacts to foreign material.
The severity depends heavily on route and volume, which is what makes this particular product a concern. Epinephrine from a vial of this size is frequently given intravenously and in urgent circumstances, sometimes as a sustained infusion — a setting with more exposure and less opportunity for careful inspection than a routine scheduled injection.
Why epinephrine specifically matters
Epinephrine is a first-line emergency drug. It is what is reached for during cardiac arrest, anaphylaxis and profound hypotension, in situations measured in seconds. Two things follow from that.
First, there is little practical opportunity for the careful visual inspection that would normally catch a cracked vial or visible particles. Second, withdrawing supply from circulation creates its own risk — a facility that quarantines stock without securing a replacement has traded a contamination hazard for an availability one. Both need managing at the same time.
What facilities and patients should do
The FDA notice instructs users to stop using the product and return it to the place of purchase or discard it. Health-care facilities should quarantine affected lots immediately, check crash cart and satellite pharmacy stock rather than only central inventory, and confirm unaffected supply is in place before removing the recalled lots from service.
American Regent can be reached at 1-800-645-1706 (customer service), 1-800-734-9236 (pharmacovigilance) and 1-888-354-4855 (product quality). Adverse events should be reported to the FDA through MedWatch.
The wider pattern behind sterile injectable recalls
This recall is a specific event, but the category it belongs to is not rare. Sterile injectables — vials, ampoules and prefilled syringes of drugs given by injection or infusion — account for a persistent share of US drug recalls and shortages, and container integrity and visible particulates are among the most common triggers.
The reasons are structural. Sterile manufacturing is unforgiving: the product cannot be terminally sterilised in every case, the filling environment must be maintained to exacting standards, and the glass container is itself part of the drug product rather than mere packaging. Many older generic injectables also sell at very low margins, which limits investment in the production lines making them, and a single facility often supplies a large share of national demand for a given presentation.
The result is a supply base where one quality problem can remove a meaningful fraction of a critical medicine from circulation — which is precisely why the instruction to secure replacement stock before quarantining matters as much as the instruction to quarantine.
How to read “no adverse events reported”
As of the announcement date, no adverse events had been reported in connection with these lots. That is genuinely reassuring, but it should be read carefully rather than as an all-clear.
Harm from injected particulates is unusually difficult to attribute. A patient who receives IV epinephrine is, by definition, critically ill, and a subsequent embolic or inflammatory event would most naturally be attributed to their underlying condition rather than to the drug container. Recall reporting also lags: complaints surface, an investigation runs, and the notice follows — while product distributed as long ago as September 2025 has been in use throughout.
The absence of reports is a reason for calm, not a reason to skip the quarantine. This is a recall notice, not medical advice; follow official FDA and manufacturer guidance.